TipRanks
111 Inc (YI)
NASDAQ:YI
Want to see YI full AI Analyst Report?

111 (YI) Price & Analysis

280 Followers

YI Stock Chart & Stats

$3.74
-$0.05(-1.45%)
At close: 4:00 PM EDT
$3.74
-$0.05(-1.45%)

Bulls Say, Bears Say

Bulls Say
Marketplace Service GrowthGrowth in marketplace service income indicates increasing monetization of 111’s digital platform even while the company reshapes its operations. A larger service-based contribution can support a more asset-light model and reduce reliance on lower-margin product distribution over time.
Promotional Pharmaceutical ExpansionRapid growth in promotional pharmaceuticals and broader pharmacy penetration shows that 111 can use its platform to scale selected products across its network. If this traction persists, it may improve product mix and create a stronger channel for manufacturers and pharmacies.
AI-Enabled Cost DisciplineLower operating and fulfillment expenses demonstrate tangible progress toward the company’s asset-light, AI-powered strategy. Sustained efficiency gains could improve operating leverage, conserve cash, and help the platform absorb weak revenue periods while the business mix changes.
Bears Say
Revenue Contraction During RestructuringThe sharp quarterly decline and lower trailing revenue indicate that the strategic shift is currently reducing business scale. Although divestitures were deliberate, sustained contraction could weaken supplier and customer reach and make it harder for the newer platform model to offset lost sales.
Negative Stockholders’ EquityPersistently negative equity signals a weak capital structure and limits financial flexibility. It can constrain the company’s ability to fund expansion internally, absorb operating setbacks, or negotiate from a position of strength with creditors and other capital providers.
Unprofitable And Volatile Cash GenerationOngoing losses and a thin gross margin leave little buffer to cover operating costs, while the return to negative operating and free cash flow raises the risk that the business will consume liquidity. Without consistent earnings and cash generation, strategic improvements may be difficult to sustain.

111 News

YI FAQ

What was 111 Inc’s price range in the past 12 months?
111 Inc lowest stock price was $2.48 and its highest was $11.17 in the past 12 months.
    What is 111 Inc’s market cap?
    111 Inc’s market cap is $27.67M.
      When is 111 Inc’s upcoming earnings report date?
      111 Inc’s upcoming earnings report date is Nov 26, 2026 which is in 48 days.
        How were 111 Inc’s earnings last quarter?
        111 Inc released its earnings results on Sep 17, 2026. The company reported -$0.656 earnings per share for the quarter.
          Is 111 Inc overvalued?
          According to Wall Street analysts 111 Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does 111 Inc pay dividends?
            111 Inc does not currently pay dividends.
            What is 111 Inc’s EPS estimate?
            111 Inc’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does 111 Inc have?
            111 Inc has 5,196,964 shares outstanding.
              What happened to 111 Inc’s price movement after its last earnings report?
              111 Inc reported an EPS of -$0.656 in its last earnings report. Following the earnings report the stock price went up 4.734%.
                Which hedge fund is a major shareholder of 111 Inc?
                Currently, no hedge funds are holding shares in YI
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Company Description

                  111 Inc

                  Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels. The company facilitates the sale of a wide array of medical and wellness products, reaching customers through its online retail channels as well as wholesale and retail pharmacy networks. This extensive product catalog encompasses prescription medications, over-the-counter drugs (both Western and traditional Chinese), dietary supplements like vitamins, optical products such as contact lenses, various medical supplies and devices (e.g., bandages, thermometers), personal care items (including skincare, birth control, and sexual wellness products), and infant care essentials. Beyond product sales, 111, Inc. provides value-added services to consumers, such as online consultation and electronic prescription fulfillment. For its business partners, the company manages an online marketplace enabling third-party vendors to directly supply pharmacies. It further supports its "1 Pharmacy" clients – comprising pharmacies and wholesalers – with online loan application services, alongside offering data and supply chain integration solutions. Its operational scope also extends to critical back-end functions, including warehousing, logistics management, procurement, research and development, consulting, as well as software development and IT support. As of December 31, 2021, its physical footprint included 14 retail pharmacies operating under the "Yi Hao Pharmacy" brand across several key regions: Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan. The company caters to a diverse clientele, encompassing individual consumers, pharmacies, pharmaceutical manufacturers and distributors, medical practitioners, and insurance providers.

                  111 (YI) Earnings & Revenues

                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Rockwell Med
                  ―
                  ―
                  Dyadic International
                  ―
                  ―
                  Rein Therapeutics
                  ―
                  ―
                  Elutia
                  ―
                  ―
                  Neuphoria Therapeutics
                  ―
                  ―

                  Ownership Overview

                  45.93%0.05%0.08%53.94%
                  45.93% Insiders
                  0.08% Other Institutional Investors
                  53.94% Public Companies and
                  Individual Investors
                  Popular Stocks